Jafron Biomedical (300529.SZ)

Overall impact
B (66)

Commentary

Jafron Biomedical is a strong overall performer. With a 'B' rating of 66.0 for overall impact (75th percentile compared to all companies), Jafron Biomedical ranks 80th out of 155 industry peers, behind American Shared Hospital Services, Accuray, Avinger and 76 others, and ahead of Hologic, Adm Tronics Unlimited, RTI Surgical and 72 others. On top material causes for Jafron Biomedical's industry (Healthcare Equipment), Jafron Biomedical performs well in Improved Mental Health (95.4 score) and Technology Innovation (95.6) and performs poorly in Child and Maternal Health (36.9 score) and Racial Justice and Civil Rights (39.0).
Impact
Cause 300529.SZ
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company

Jafron Biomedical

Employees
2,200
Sector
Health Care
Industry
Health Care Equipment & Supplies
Sub-industry
Health Care Equipment
SASB industry
Medical Equipment & Supplies
Headquarters
China
Share classes
300529.SZ
Description
Jafron Biomedical Co.,Ltd. engages in the research, development, production, and sales of blood purification products for hemadsorption field in worldwide. The company provides solutions for ESRD diseases, acute poisoning, critical illness, hepatopathy, immunological disorders, kidney, and liver diseases. It offers HA series hemoperfusion cartridge, BS series bilirubin adsorption column and DNA immunoadsorption column, hemoperfusion machine, and blood purification machine; and other products, such as hemodialyzer, disinfectants, hemodialysis concentrate, resin bandages, online hemodialysis powder bag/bucket, and adsorbable suture with needles, as well as syringe and infusion pumps. The company was founded in 1989 and is based in Zhuhai, China.
Material causes
Ethos considers the following causes material for Jafron Biomedical, based on its industry sub-industry Health Care Equipment. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.